Nymox Pharmaceutical Corporation Share Price
Equities
NYMXF
BSP733981026
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3 USD | 0.00% | +3.38% | -49.15% |
Sales 2021 | - | Sales 2022 | - | Capitalization | 29.51M 2.36B |
---|---|---|---|---|---|
Net income 2021 | -12M -961M | Net income 2022 | -6M -480M | EV / Sales 2021 | - |
Net cash position 2021 | 439K 35.15M | Net cash position 2022 | 1.23M 98.49M | EV / Sales 2022 | - |
P/E ratio 2021 |
-8.5
x | P/E ratio 2022 |
-4.39
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.95% |
1 week | +3.38% | ||
Current month | -25.00% | ||
1 month | -28.57% | ||
3 months | -31.82% | ||
6 months | -70.00% | ||
Current year | -49.15% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 29/05/95 |
Patrick Doody
BRD | Director/Board Member | - | 11/07/23 |
Director/Board Member | - | 20/03/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 07/06/06 |
Paul Averback
CEO | Chief Executive Officer | 73 | 29/05/95 |
Director/Board Member | 88 | 30/06/15 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.3 | 0.00% | 3,833 |
25/04/24 | 0.3 | -6.25% | 419 |
24/04/24 | 0.32 | +6.67% | 1,752 |
23/04/24 | 0.3 | 0.00% | 3,816 |
22/04/24 | 0.3 | +3.38% | 20,126 |
Delayed Quote OTC Markets, April 26, 2024 at 08:33 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-49.15% | 28.01M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NYMXF Stock